UNSPSC 51434402: Tinabinol

This classification denotes an antihypertensive agent with the molecular formula C23H34O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 455Y914AKK, chemically known as 1,2,3,5-tetrahydro-5,5-dimethyl-8-(1,2-dimethylheptyl)thiopyrano(2,3-c)(1)benzopyran-10-ol but generally known as tinabinol, which bears US NIH Compound Identifier 65443. European Medicines Agency schedules Tinabinol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11072MIG.

UNSPSC 51434402 Tinabinol, a Commodity code, covers emergency and acute-care medications supplied to state and local public health agencies, fire rescue services, and pharmacy benefit programs. State and local governments procure under this code specific life-support drugs — epinephrine, labetalol, adenosine, diltiazem, and related injectables — for use by paramedic and emergency medical services, as well as generic multi-source pharmaceuticals for distribution through state health and human services agency networks and cooperative purchasing vehicles. Issuing bodies include municipal fire departments, state health and human services commissions, and state procurement offices administering multistate cooperative purchasing alliances. The work involves either direct supply of medications to emergency responders or enrollment as a manufacturer in cooperative pharmaceutical frameworks that aggregate demand across multiple state and local jurisdictions.

Recent activity spans Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued IFB 26P00188 in April 2026 to supply Advanced Life Support Medications (labetalol, epinephrine, adenosine, and diltiazem) to Tampa Fire Rescue, with sealed bids due April 8, 2026 and an estimated contract value of $40,000.00; the solicitation included a Small Local Business Enterprise sheltered market designation with a 5 percent bid discount. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026, requiring vendors to maintain relationships with authorized wholesalers and comply with cGMP and Drug Supply Chain Security Act standards. The Texas Health and Human Services Commission issued RFI HHS0017013 in March 2026 to solicit vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling preliminary interest in direct contracting models outside traditional pharmacy benefit manager and wholesaler channels.